This text investigates the molecular mechanisms, clinical progression, and therapeutic management of Chronic Myeloid Leukaemia (CML). The authors, a panel of distinguished hematologists and researchers, synthesize decades of clinical data and laboratory findings to provide a comprehensive framework for understanding the BCR-ABL1 oncogene and its role in disease pathogenesis. The book details the evolution of treatment protocols, ranging from traditional chemotherapy to the development of targeted tyrosine kinase inhibitors.

Experts in the field of hematology recognize this work as a rigorous reference for clinicians and researchers focusing on myeloid malignancies. Readers frequently note the technical density of the prose, which assumes a foundational understanding of cellular biology and clinical oncology.